Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9816-9826

  Brignole, Chiara ^a   Marimpietri, Danilo ^a   Di Paolo, Daniela ^a   Perri, Patrizia ^a   Morandi, Fabio ^a   Pastorino, Fabio ^a   Zorzoli, Alessia ^a   Pagnan, Gabriella ^a   Loi, Monica ^a   Caffa, Irene ^a   Erminio, Giovanni ^a   Haupt, Riccardo ^a   Gambini, Claudio ^a   Pistoia, Vito ^a   Ponzoni, Mirco ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CPG OLIGODEOXYNUCLEOTIDE; LIPOSOME; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOSOMAL DELIVERY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LIPOSOMES; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, NUDE; MICE, SCID; NEOPLASM STAGING; NEUROBLASTOMA; OLIGODEOXYRIBONUCLEOTIDES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 9; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649953595     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1251     Document Type: Article

References (48)

1. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95. (Pubitemid 41057715)
2. Hornef MW, Bogdan C. The role of epithelial Toll-like receptor expression in host defense and microbial tolerance. J Endotoxin Res 2005;11:124-8. (Pubitemid 40711489)
3. Schmausser B, Andrulis M, Endrich S, Lee SK, Josenhans C, Muller-Hermelink HK, et al. Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 2004;136: 521-6.
4. Zeromski J, Mozer-Lisewska I, Kaczmarek M. Significance of Toll-like receptors expression in tumor growth and spreading: a short review. Cancer Microenviron 2008;1:37-42.
5. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65:5009-14. (Pubitemid 40827306)
6. Krieg AM. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84.
7. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004;5:190-8. (Pubitemid 38208361)
8. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009;61: 195-204.
9. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
10. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
11. Brignole C, Pastorino F, Marimpietri D, Pagnan G, Pistorio A, Allen TM, et al. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J Natl Cancer Inst 2004;96:1171-80. (Pubitemid 39207053)
12. Brignole C, Marimpietri D, Pastorino F, Di Paolo D, Pagnan G, Loi M, et al. Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides. J Control Release 2009; 138:122-7.
13. Pagnan G, Stuart DD, Pastorino F, Raffaghello L, Montaldo PG, Allen TM, et al. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst 2000; 92:253-61.
14. Stuart DD, Allen TM. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim Biophys Acta 2000;1463:219-29.
15. Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D, et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res 2003;9:4595-605. (Pubitemid 37248420)
16. Bogenmann E. A metastatic neuroblastoma model in SCID mice. Int J Cancer 1996;67:379-85. (Pubitemid 26274129)
17. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, et al. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 1995;55:853-61.
18. Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F, et al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res 2007;13:3977-88.
19. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002;32:1372-4, 6, 8-9.
20. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, et al. Effect of Bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006;98:1142-57.
21. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
22. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001;98:9237-42. (Pubitemid 32743900)
23. Corrias MV, Guarnaccia F, Ponzoni M. Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules. J Neurooncol 1997;31: 171-80. (Pubitemid 27077725)
24. Giles RV, Spiller DG, Grzybowski J, Clark RE, Nicklin P, Tidd DM. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. Nucleic Acids Res 1998;26:1567-75. (Pubitemid 28291789)
25. Lakhani SA, Masud A, Kuida K, Porter GA Jr., Booth CJ, Mehal WZ, et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006;311:847-51. (Pubitemid 43228848)
26. Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 2003;171:1393-400. (Pubitemid 36900072)
27. Murchie AI, Lilley DM. Tetraplex folding of telomere sequences and the inclusion of adenine bases. EMBO J 1994;13:993-1001.
28. Yamada H, Gursel I, Takeshita F, Conover J, Ishii KJ, Gursel M, et al. Effect of suppressive DNA on CpG-induced immune activation. J Immunol 2002;169:5590-4. (Pubitemid 35291658)
29. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008;456:658-62.
30. Higuchi Y, Kawakami S, Oka M, Yamashita F, Hashida M. Suppression of TNFalpha production in LPS induced liver failure in mice after intravenous injection of cationic liposomes/NFkappaB decoy complex. Pharmazie 2006;61:144-7. (Pubitemid 43293898)
31. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO, et al. RNA interference in vitro and in vivo using a novel chitosan/ siRNA nanoparticle system. Mol Ther 2006;14:476-84. (Pubitemid 44296092)
32. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody- mediated cytolysis and suppression of tumor growth. Cancer Res 1987;47:1098-104. (Pubitemid 17027936)
33. Wargalla UC, Reisfeld RA. Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc Natl Acad Sci U S A 1989;86:5146-50.
34. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997;89:1586-94. (Pubitemid 27479718)
35. Wu QL, Buhtoiarov IN, Sondel PM, Rakhmilevich AL, Ranheim EA. Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. J Immunol 2009;182:6771-8.
36. Serreze DV, Gaedeke JW, Leiter EH. Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci U S A 1993;90:9625-9.
37. Detre S, Saclani Jotti G, Dowsett M. A 'quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-8.
38. Hassan F, Islam S, Tumurkhuu G, Naiki Y, Koide N, Mori I, et al. Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer 2006;6:281. (Pubitemid 46017459)
39. Rayburn ER, Wang W, Zhang Z, Li M, Zhang R, Wang H. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 2006;66:1653-63. (Pubitemid 44646356)
40. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival ofmice with experimental brain tumors. Glia 2006;54: 526-35. (Pubitemid 44449333)
41. Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 2007;6:1704-9.
42. van Loo G, Saelens X, Matthijssens F, Schotte P, Beyaert R, Declercq W, et al. Caspases are not localized in mitochondria during life or death. Cell Death Differ 2002;9:1207-11. (Pubitemid 35331767)
43. Ma L, Zhao G, Hua C, Li X, Zhao X, Sun L, et al. Down-regulation of TLR9 expression affects the maturation and function of murine bone marrow-derived dendritic cells induced by CpG. Cell Mol Immunol 2009;6:199-205.
44. Allen TM, Cheng WW, Hare JI, Laginha KM. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem 2006;6:513-23.
45. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62:7190-4. (Pubitemid 36025236)
46. Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, et al. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res 2008;14:7320-9.
47. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006;66:10073-82.
48. Wagner-Ballon O, Chagraoui H, Prina E, Tulliez M, Milon G, Raslova H, et al. Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin. J Immunol 2006;176:6425-33. (Pubitemid 43787824)